Can Tremfya cause cancer?
There is a slightly higher risk of non-melanoma skin cancers (NMSC) in people taking Tremfya compared with those taking adalimumab but combined data from clinical trials indicate that apart from NMSC and cervical cancer in situ, the risk of cancer is not increased in people taking Tremfya compared to the general US population.
In the Voyage 1 study, 0.6% of Tremfya-treated patients (2 out of 329) and 0.3% of adalimumab-treated patients (1 out of 333) developed basal cell carcinomas (BCC) after 48 weeks. Other cancers, such as those of the breast or prostate, occurred in 0.6% of patients treated with Tremfya. In the Voyage 2 study, 3 patients treated with Tremfya developed either BCC or squamous cell carcinoma. Prostate cancer occurred in one Tremfya patient.
After 3 years of treatment in the Voyage 1 or 2 studies, 32 patients in total reported malignancies; 14 of these had NMSC and 19 had a malignancy other than NMSC. The most common cancers reported were those of the prostate or breast.
Most clinical trials investigating Tremfya excluded people from participating in the trial if they had current cancer or a previous history of cancer. There is also evidence to show that people with psoriasis have an inherent increased risk of developing several different malignancies including NMSC and lymphoma.
Related medical questions
- What are monoclonal antibodies?
- How long does it take for Tremfya to work?
- How and where do you inject Tremfya?
- Can Tremfya cause cancer?
- How long can Tremfya be out of the fridge?
- Is Tremfya a biological?
- What are monoclonal antibodies?
- How long does it take for Tremfya to work?
- How and where do you inject Tremfya?
- How long can Tremfya be out of the fridge?
- Can Tremfya cause cancer?
- Is Tremfya a biological?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions